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α‐BTX

:   α‐bungarotoxin

BAPTA‐AM

:   1,2‐bis(2‐aminophenoxy)ethane‐*N*,*N*,*N*′,*N*′‐tetraacetic acid tetrakis (acetoxymethyl ester)

[blast]{.smallcaps}P

:   protein--protein [blast]{.smallcaps}

DHβE

:   dihydro‐β‐erythroidine

DMPP

:   dimethyl‐4‐phenyllpiperazinium iodide

dTC

:   d‐tubocurarine

GHK

:   Goldman Hodgkin Katz

MLA

:   methyllycaconitine

nAChR

:   nicotinic ACh receptor

PAM

:   positive allosteric modulator

Tables of Links {#bph13524-sec-0005}
===============

**TARGETSLigand--gated ion channels**[Asu‐ACR‐16](http://www.wormbase.org/species/c_elegans/protein/WP:CE09639?redirect=1#067235--10)[ACR‐16](http://www.wormbook.org/chapters/www_anthelminticdrugs.2/anthelminticdrugs.2.html)[Nicotinic ACh receptor α7 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468)**LIGANDS**[A844606](https://pubchem.ncbi.nlm.nih.gov/compound/11461365#section=Top)[Dimethyl‐4‐phenyllpiperazinium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%203967)[Morantel](https://pubchem.ncbi.nlm.nih.gov/compound/morantel#section=Top)[Acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294)[Epibatidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%205348)[Nicotine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585)[Bephenium](https://pubchem.ncbi.nlm.nih.gov/compound/bephenium_hydroxynaphthoate#section=Top)[Genistein](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%202826)[Oxantel](https://pubchem.ncbi.nlm.nih.gov/compound/oxantel_pamoate#section=Top)[Betaine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4550)[Hexamethonium](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%203963)[Paraherquamide](https://pubchem.ncbi.nlm.nih.gov/compound/156934#section=Top)[Bromocytisine](https://pubchem.ncbi.nlm.nih.gov/compound/5-Bromocytosine#section=Chemical-Vendors)[Ivermectin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%202373)[PNU120596](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3991)[α‐Bungarotoxin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964)[Levamisole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7210)[Pyrantel](https://pubchem.ncbi.nlm.nih.gov/compound/pyrantel_pamoate#section=Top)[Choline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%204551)[Lobeline](https://pubchem.ncbi.nlm.nih.gov/compound/3945#section=Top)[Thenium](https://pubchem.ncbi.nlm.nih.gov/compound/thenium_closylate#section=Top)[Cytisine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%205347)[Mecamylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%203990)[Tribendimidine](https://pubchem.ncbi.nlm.nih.gov/compound/Tribendimidine#section=Top)[Derquantel](https://pubchem.ncbi.nlm.nih.gov/substance/198985723#section=Top)[Methyllycaconitine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4005)[d‐Tubocurarine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%20%202294)[Dihydro‐β‐erythroidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=%204006)[Methyridine](https://pubchem.ncbi.nlm.nih.gov/substance/274408787#section=Top)[^1]

Introduction {#bph13524-sec-0006}
============

Soil‐transmitted helminths (gastrointestinal nematode parasites) cause significant global health problems in humans and animals. It is estimated that at least one‐quarter of the world\'s human population (Brooker, [2010](#bph13524-bib-0014){ref-type="ref"}) and most animal species are infected with parasitic worms. Nematode parasite infections have a high morbidity and cause debilitating conditions such as weight loss, anaemia, compromised immunity, impaired learning ability and, in severe cases, death (Hotez *et al.*, [2007](#bph13524-bib-0029){ref-type="ref"}). No current vaccine against nematode parasite infections of humans is effective (Hewitson and Maizels, [2014](#bph13524-bib-0027){ref-type="ref"}), so control of these infections relies on chemotherapy. Regrettably, there are a limited number of classes of anthelmintics (Martin, [1997](#bph13524-bib-0041){ref-type="ref"}; Kaminsky *et al.*, [2008](#bph13524-bib-0032){ref-type="ref"}), which, with the repeated large scale use of the drugs, has led to the development of resistance in animals (Wolstenholme *et al.*, [2004](#bph13524-bib-0062){ref-type="ref"}), and concerns about the development of resistance in humans (Taman and Azab, [2014](#bph13524-bib-0057){ref-type="ref"}). The increasing resistance means that novel drug targets are required to overcome this resistance.

Nicotinic ACh receptors (nAChRs) of vertebrates and invertebrates serve a very wide range of functions. For example, in excitable cells, they are involved in neuronal and neuromuscular transmission and, in non‐excitable cells, are involved in modulation, development of growth and differentiation (Wessler and Kirkpatrick, [2008](#bph13524-bib-0060){ref-type="ref"}). Nematode parasite nAChRs are pharmacologically different to their host nAChRs and are validated and exploited anthelmintic drug targets (Gopalakrishnan *et al.*, [2007](#bph13524-bib-0025){ref-type="ref"}). All nAChRs are five‐subunit ligand‐gated ion channels which open in the presence of ACh or choline, and are found on muscles, nerves, secretory cells and a wide range of non‐excitable tissues in both vertebrates and invertebrates. The pharmacology of individual nAChRs depends on key amino acid sequences of each nAChR subunit of the pentamer and the composition of the subunits that form the receptor. The subunits that make up vertebrate nAChRs are derived from at least 17 genes (α1--α10, β1--β4, γ, δ, ϵ) (Karlin, [1993](#bph13524-bib-0034){ref-type="ref"}; Millar and Gotti, [2009](#bph13524-bib-0046){ref-type="ref"}) and from 29 genes in the free‐living nematode, Caenorhabditis elegans (Jones *et al.*, [2007](#bph13524-bib-0030){ref-type="ref"}). The subunits of the pentameric receptor channel may be composed of five identical subunits (homomeric) or a mixture of different subunits (heteromeric) arranged around a central ion conducting pore (Chen, [2010](#bph13524-bib-0017){ref-type="ref"}).

The older, cholinergic anthelmintics, levamisole and pyrantel, and the more recently introduced anthelmintics, tribendimidine and derquantel, activate heterogeneous pentameric nAChRs composed of a mixture of UNC‐29, UNC‐38, ACR‐8 or UNC‐63 subunits (Buxton *et al.*, [2014](#bph13524-bib-0016){ref-type="ref"}). The more recently introduced cholinergic anthelmintic, monepantel, activates nAChRs composed of a mixture of DEG‐3‐like subunits, including ACR‐23, ACR‐20 and MPTL‐1 (Baur *et al.*, [2015](#bph13524-bib-0004){ref-type="ref"}). Resistance to some of these anthelmintics has been observed in animal parasites (McMahon *et al.*, [2013](#bph13524-bib-0045){ref-type="ref"}; Scott *et al.*, [2013](#bph13524-bib-0054){ref-type="ref"}), and although the mechanism(s) of field resistance have not been well characterized, there is evidence that the resistance can involve altered subunit sequence or subunit truncation (Fauvin *et al.*, [2010](#bph13524-bib-0023){ref-type="ref"}; Neveu *et al.*, [2010](#bph13524-bib-0048){ref-type="ref"}).

Here, we have cloned and expressed, in *Xenopus* oocytes, *acr‐*16 cRNA from *Ascaris suum*, a clade III nematode parasite, which is very similar to the significant human parasite, *A. lumbricoides*. This receptor was expressed as a homomeric receptor in *Xenopus* oocytes, and transcripts are found in muscle, intestine, reproductive tract and other tissues of the *Ascaris* body, suggesting diverse physiological functions in addition to neuromuscular transmission. Knowing that ACR‐16 is a nicotine‐sensitive nAChR and that nicotine has in the past been used as the drug of choice for treatment of Ascaridia galli infections (Kerr and Cavett, [1952](#bph13524-bib-0036){ref-type="ref"}), a selective drug targeted against ACR‐16 could affect motility, digestion and reproduction of parasites and be an effective anthelmintic.

Methods {#bph13524-sec-0007}
=======

Animals {#bph13524-sec-0008}
-------

No vertebrate animals were used directly in the study. Adult female *A.suum* worms were collected from Marshalltown Pork Plant, Marshalltown, IA, USA. Defolliculated Xenopus laevis oocytes were obtained from Ecocyte Bioscience (Austin, TX, USA).

Sequence analysis {#bph13524-sec-0009}
-----------------

For convenience, the sources of the AChR subunits are indicated, in this article, by three letter prefixes. Thus, *Ace*, *Asu*, *Cel*, *Hco*, *Llo*, *Nam*, *Sra, Tca and Xle*, refer to *Ancylostoma ceylanicum*, *Ascaris suum*, Caenorhabditis elegans, *Haemonchus contortus*, *Loa loa*, Necator americanus, *Strongyloides ratti, Toxocara canis* and *Xenopus laevis* respectively.

Database searches around the sequence of *Asu*‐ACR‐16 were performed with the [blast]{.smallcaps} Network Service (NCBI), using the protein--protein [blast]{.smallcaps} ([blast]{.smallcaps}P) algorithm (Altschul *et al.*, [1997](#bph13524-bib-0001){ref-type="ref"}). Signal peptide predictions were carried out using the SignalP 4.0 server (Bendtsen *et al.*, [2004](#bph13524-bib-0005){ref-type="ref"}), and membrane‐spanning regions were predicted using TMpred (Hofmann and Stoffel, [1993](#bph13524-bib-0028){ref-type="ref"}). Distance trees were generated on the full‐length deduced amino acid sequences aligned with the MUSCLE programme (Edgar, [2004](#bph13524-bib-0022){ref-type="ref"}). The alignment was analysed using the SEAVIEW suite (Gouy *et al.*, [2010](#bph13524-bib-0026){ref-type="ref"}) with the neighbour‐joining method and bootstrapped with 1000 replicates. The resulting tree was visualized and edited using FigTree 1.4 ([http://tree.bio.ed.ac.uk/software/figtree/](http://www.google.com/url?PARAMS=xik_N7zrZcyvsMi7EkvoBUcLqTmU6v1MJri1Hpb1SjdpaaNv2ZsakHv4bZzzWh3HT9ejBMNHg1hjxZ17LvRriGGKsGtPtqFndnT45YfHicQFgrKMFeqNof6maA4MGKYafLZguvwMJhYDf9kZ8TJsBSTmWXGda8ufwuD3mjNBSayqWPfJzCj)).

Asu‐ACR‐16 receptor localization {#bph13524-sec-0010}
--------------------------------

Total RNA was extracted with TRIzol (Invitrogen™, Carlsbad, CA, USA) from different body tissues of five dissected adult female *Asu* worms. The tissues were the gut, ovijector, head, single muscle cells (RNA extracted via micropipette), bulk somatic muscle, single muscle cells of the pharynx (RNA extracted via micropipette) and bulk muscle cells of the pharynx. Specific primers were designed for PCR for *acr‐*16 (forward primer GACTTGCAACCAGGCAAAGG; reverse primer ACGGGTCGTTATGCCCATTT) and *gapdh* (positive control) (forward primer CTGCTGGACCAATGAAGGGT; reverse primer CACTCCACTCACAGCCACTT) using the online Primer‐[blast]{.smallcaps} tool. With these primer sets, the expected product size for *acr‐*16 was 468 and 411 bp for *gapdh*. The presence or absence of *acr‐*16 in the RNA samples was detected using RT‐PCR and single‐cell RT‐PCR (QIAGEN OneStep RT‐PCR Kit; Valencia, CA, USA) at an annealing temperature of 55°C and for 45 PCR cycles. The PCR products from both RT‐PCR and single‐cell RT‐PCR were run on a 1% agarose gel, at the end of which the gel was viewed and captured on a UVP BioSpectrum Multi Spectral Imaging System (UVP LLC, Upland, CA, USA). Representative bands were sequenced to confirm the identity of *acr‐*16.

cRNA preparation {#bph13524-sec-0011}
----------------

Total RNA samples were extracted with TRIzol (Invitrogen™) from a 1 cm muscle flap and dissected whole pharynx of *Asu*. RT‐PCR was used to synthesize first‐strand cDNA from muscle and pharynx total RNA with both oligo (dT) RACER primer and Random Hexamer, and superscript III reverse transcriptase (Invitrogen). To amplify the full‐length coding sequence of *Asu‐ACR‐*16, specific primer pairs were designed on the putative 5′‐ and 3′‐UTRs mRNA sequence deduced from *Asu* whole genome shotgun contig N°AEUI02000378 (*Asu*‐acr‐16‐F0 ATCACGCATTACGGTTGATG, *Asu*‐acr‐16‐F1 TTGATGTAGTGGCGTCGTGT, *Asu*‐acr‐16‐R0 ATTAGCGTCCCAAGTGGTTG, *Asu*‐acr‐16‐R1 GCATTGATGTTCCCTCACCT) for a first round of PCRs. We used a classical nested PCR approach with F0/R0, F0/R1, F1/R0 and F1/R1 respectively to perform four separate PCR reactions for the first round to increase the chance of amplification success. These four PCR products were subsequently used as templates for a second round of four separate PCR reactions using the following specific primers containing *Hind*III and *Apa*I restriction enzyme sites (*Asu*‐acr‐16‐F‐Hind3AAAAAGCTTATGAGCGTGCAGCGGGCATT, *Asu*‐acr‐16‐R‐*Apa*I TTTGGGCCCTAGAGTGCTGATGATGTGCTA) to facilitate directional cloning into the PTB‐207 expression vector. PCR products were then digested with *Hind*III and *Apa*I restriction enzymes, purified using the NucleoSpin® Gel and PCR Clean‐up kit (Macherey‐Nagel Inc. Bethlehem, PA, USA), cloned into PTB‐207 as previously described (Boulin *et al.*, [2011](#bph13524-bib-0011){ref-type="ref"}) and sequenced. A positive clone was selected and linearized with NheI for subsequent *in vitro* transcription with the mMessage mMachine T7 transcription kit (Ambion). The cRNA was precipitated with lithium chloride, resuspended in RNAse‐free water, aliquoted and stored at −80°C.

Oocyte microinjection {#bph13524-sec-0012}
---------------------

The Xenopus oocytes were kept at 19°C for \~3 h prior to injections in incubation solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2~.2H~2~0, 1 mM MgCl~2~.6H~2~0, 5 mM HEPES, 2.5 mM Na pyruvate, 100 U·mL^−1^ penicillin and 100 μg·mL^−1^ streptomycin, pH 7.5). Depending on the cRNA mix, 10--25 ng of *acr‐*16 cRNA either alone or in combination with 2.5--15 ng of each ancillary (*ric‐*3, *unc‐*50 and *unc‐*74), in a total volume of 50 nL in RNAse‐free water, was injected into the animal pole of the oocytes using a nanoject II microinjector (Drummond Scientific, Broomall, PA, USA). The injected oocytes were transferred into 96‐well culture plates containing 200 μL incubation solution per well; each well contained one oocyte. Oocytes were incubated at 19°C for 2--7 days to allow for receptor expression; incubation solution was changed daily. Oocytes with membrane potentials less than −15 mV were excluded from recording. Oocyte recordings that failed (shown by a change in the holding current following wash) before the complete series of drug applications were excluded from the analysis.

Two‐electrode voltage clamp electrophysiology in Xenopus oocytes {#bph13524-sec-0013}
----------------------------------------------------------------

Two‐electrode voltage clamp electrophysiology was used to record currents produced by activation of the expressed *Asu*‐ACR‐16 receptor (Buxton *et al.*, [2014](#bph13524-bib-0016){ref-type="ref"}). Four hours prior to recording, 100 μM BAPTA‐AM (final concentration), a cell‐permeant calcium chelator, was added to the oocyte incubation solution to prevent activation of endogenous calcium‐activated chloride channels during recordings. Recordings from non‐injected oocytes served as control experiments. Recordings were made using an Axoclamp 2B amplifier (Warner Instruments, Hamden, CT, USA) with the oocytes voltage clamped at −60 mV and data acquired on a computer with Clampex 9.2 (Molecular Devices, Sunnyvale, CA, USA). The microelectrodes used to impale the oocytes were pulled using a Flaming/Brown horizontal electrode puller (Model P‐97; Sutter Instruments, Novato, CA, USA) set to pull micropipettes that when filled with 3 M KCl had a resistance of 20--30 MΩ. The micropipettes tips were carefully broken with a piece of tissue paper in order to achieve a resistance of 2--5 MΩ in recording solution (100 mM NaCl, 2.5 mM KCl, 1 mM CaCl~2~.2H~2~O and 5 mM HEPES, pH 7.3). The low resistance pipettes allowed large currents to be passed to maintain adequate voltage clamp.

Assessment of agonists and antagonists {#bph13524-sec-0070}
--------------------------------------

Except where indicated, agonists were used at a final concentration of 100 μM, while the antagonists were used at a final concentration of 10 μM for rank order potency experiments and 1 μM for the dose--response experiments. Effects of the positive allosteric modulators (PAMs): ivermectin (10 μM), genistein (3 μM) and PNU120596 (3 μM), were tested. Control responses were obtained first with agonists applied for 10 s. Responses were again observed after the antagonists or PAMs were applied for 2 min and observed in the continued presence of antagonist or PAM. In the case of the antagonist rank order potency experiments, a control application of 100 μM ACh was first applied for 10 s, immediately followed by a test 10 s application of antagonist in the continued presence of 100 μM ACh and then a final 10 s application of 100 μM ACh. Note that, with this approach, the potency for each antagonist is likely to be slightly underestimated due to the short time of drug application. In order to minimize desensitization effects, at least 2 min was allowed for drug wash off between applications.

Dose--response studies were conducted in ascending order of concentrations and were not presented randomly. This approach minimizes desensitization by high concentrations of agonist. The application of the sequence of agonists for determining the potency series was random and not predetermined.

Blinding was not used because it was necessary to allow the appropriate technique and study methods to be used to test if the drug was a potential agonist, potential antagonist or potential PAM. In all our recordings, we applied an initial 100 μM ACh control, and all other responses were normalized to this control 100 μM ACh current. The normalized ACh current (100%) was not used for statistical analysis. Log dose--response plots are used for display and determination of the EC~50~, *nH* and maximum response.

Permeability of receptors to calcium {#bph13524-sec-0069}
------------------------------------

Calcium permeability experiments were conducted by increasing the external Ca^2^ ^+^ concentration from 1 to 10 mM in the recording solution without changing the concentration of other cations. Oocytes were challenged with 30 μM ACh in the recording solution, with the membrane of the oocytes held at different potentials between −60 and +30 mV. The Goldman Hodgkin Katz (GHK) constant field equation was used to calculate the permeability ratio, *P* ~*Ca*~/*P* ~*Na*~. Because the oocytes were BAPTA‐treated prior to recording, the assumptions made in calculating the permeability ratio of the expressed *Asu*‐ACR‐16 receptor were that the internal \[Ca^2^ ^+^\] is negligible and permeability of Na and K, *P* ~*Na*~ and *P* ~*K*~ is equal. Ionic activity coefficients used for the calculations were 0.56 for Ca^2^ ^+^ and 0.72 for Na^+^ and K^+^. The GHK equation (with ionic activity inserted) used in calculating the *P* ~*Ca*~/*P* ~*Na*~ was $$\left. E_{\mathit{rev}} = \mathit{RT}/F\mspace{9mu}\ln\left\{ \left( {P_{\mathit{Na}}*0.72\left\lbrack \mathit{Na} \right\rbrack_{o} + P_{K}*0.72\left\lbrack K \right\rbrack_{o} + 4P'*0.56\left\lbrack \mathit{Ca} \right\rbrack_{o}} \right)/P_{\mathit{Na}}*0.72\left\lbrack \mathit{Na} \right\rbrack_{i} + P_{K}*0.72\left\lbrack K \right\rbrack_{i} \right\}, \right.$$where *E* ~*rev*~ is the reversal potential (potential at which current changes direction), *R* is the universal gas constant (8.314 J·K^−1^·mol^−1^), *T* is room temperature in Kelvin (298 K), *F* is Faraday\'s constant (96 485 C·mol^−1^) and *P*′ = *P* ~*Ca*~/*P* ~*Na*~{1/(1 + *e* ^*FErev*/*RT*^)}.

Data and statistical analysis {#bph13524-sec-0014}
-----------------------------

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis *et al*., [2015](#bph13524-bib-0021){ref-type="ref"}). The acquired data from electrophysiological recordings were analysed with Clampfit 9.2 (Molecular Devices, Sunnyvale, CA, USA) and GraphPad Prism 5.0 (Graphpad Software Inc., La Jolla, CA, USA). In all recordings, the peak currents in response to applied drugs were measured, and except where otherwise indicated, peak current values obtained were normalized to 100 μM ACh and expressed as mean ± SEM. Dose--response relationships were analysed by fitting log dose--response data points with the Hill equation as previously described (Boulin *et al.*, [2008](#bph13524-bib-0012){ref-type="ref"}), while desensitization kinetics in response to the potent agonists were fitted using a single exponential decay fit: $$f\left( t \right) = \sum_{i = 1}^{n}A_{i}e^{- \frac{t}{\tau}}\, i + C$$

where *n* is the number of components, *A* the amplitude, *t* the time, Ʈ the time constant and C the constant *y*‐offset for each *i* component.

The group sizes varied with the type of experiment performed, as described below. To optimize our expression and recording conditions, we injected 10 ng of *Asu*‐acr‐16 alone and with 1.8 ng each of the ancillary factors, *ric‐*3, *unc‐*50 and *unc‐*74 from *A.suum*, H. contortus and X.laevis (*n* = 21 for *Asu‐acr‐*16 alone; *n* = 15 for *Asu‐acr‐*16 + *Hco‐ric‐*3, *Hco‐unc‐*50 and *Hco‐unc‐*74; *n* = 15 for *Asu‐acr‐*16 + *Asu‐ric‐*3, *Asu‐unc‐*50 and *Asu‐unc‐*74; *n* = 17 for *Asu‐acr‐*16 + *Hco‐ric‐*3; *n* = 20 for *Asu‐acr‐*16 + *Xle‐ric‐*3; and *n* = 23 for *Asu‐acr‐*16 + *Asu‐ric‐*3). We found that *Asu‐unc‐*50 and *Asu‐unc‐*74 were not required for expression and that *Asu‐acr‐*16 + *Asu‐ric‐*3 produced the large robust currents (290.6 ± 63.7, *n* = 23). We also tested different amounts of *Asu‐acr‐*16 and *Asu‐ric‐*3 (*n* = 6 for 25 ng *Asu‐acr‐*16 + 5 ng *Asu‐ric‐*3, *n* = 6 for 10 ng *Asu‐acr‐*16 + 5 ng *Asu‐ric‐*3, *n* = 6 for 10 ng *Asu‐acr‐*16 + 10 ng *Asu‐ric‐*3 and *n* = 6 for 15 ng *Asu‐acr‐*16 + 15 ng *Asu‐ric‐*3) and observed that the size of the currents depended on the amount of *Asu‐acr‐*16 and *Asu‐ric‐*3 injected.

Thereafter, we injected 25 ng *Asu‐acr‐*16 + 5 ng *Asu‐ric‐*3 (which produced the biggest currents) for all subsequent experiments. For nAChR agonists and cholinergic anthelmintics, we tested larger numbers of oocytes (*n* = 21 for nicotine, *n* = 21 for cytisine, *n* = 15 for 3‐bromocytisine, *n* = 15 for epibatidine, *n* = 21 for DMPP, *n* = 36 for oxantel, *n* = 15 for choline, *n* = 15 for betaine, *n* = 15 for lobeline, *n* = 15 for A844606, *n* = 21 for morantel, *n* = 21 for levamisole, *n* = 15 for methyridine, *n* = 15 for thenium, *n* = 15 for bephenium, *n* = 15 for tribendimidine and *n* = 15 for pyrantel) to measure and examine variability of responses between oocytes. Once we had confirmed the reproducible nature of the responses (the mean and standard errors for each of the nAChR agonist and cholinergic anthelmintics shown in Figure [4](#bph13524-fig-0004){ref-type="fig"}), we reduced our *n* number to 6 for all other experiments, except the antagonist experiment where the *n* number was 5.

Data were analysed statistically as follows. All completed drug application sequences on the oocytes were used for analysis without exclusion. If the recording became unstable, indicated by a change in the baseline holding current, all of that recording was rejected for analysis. Statistical analyses were performed on groups of values using ANOVA to determine if the group means are similar and if there was variance inhomogeneity (Bartlett\'s test). *Post hoc* tests (Tukey\'s multiple comparison test for Figures [3](#bph13524-fig-0003){ref-type="fig"}B, [4](#bph13524-fig-0004){ref-type="fig"} and [7](#bph13524-fig-0007){ref-type="fig"}A; Dunnett\'s test to compare with control, for Figure [5](#bph13524-fig-0005){ref-type="fig"}) were used to determine significance of differences between groups. We analysed the effects of PAMs on *Asu*‐ACR‐16 using two‐way ANOVA. We defined *P* \< 0.05 as showing statistical significance.

Materials {#bph13524-sec-0015}
---------

The drugs used in this study, with the exception of paraherquamide, tribendimidine and derquantel were purchased from Sigma‐Aldrich (St Louis, MO, USA), Tocris Bioscience (Ellisville, MO, USA) or Calbiochem (San Diego, CA, USA). The drugs were solubilized in recording solution, DMSO or ethanol. Paraherquamide and derquantel were gifts from Zoetis (Kalamazoo, MI, USA) and tribendimidine was a gift of Prof Shu Hua Xiao (National Institute of Parasitic Diseases, China).

Results {#bph13524-sec-0016}
=======

Identification of Asu‐ACR‐16 sequence {#bph13524-sec-0017}
-------------------------------------

We used the *Cel*‐ACR‐16 sequence (Supporting Information Fig. [S1](#bph13524-supitem-0001){ref-type="supplementary-material"}) as a query in a [blast]{.smallcaps}P search in protein databases from nematodes which allowed the identification of a potential complete coding sequence of an ACR‐16 homologue in the pig parasite *Asu* (ERG81952.1). RT‐PCR experiments using primers designed using this predicted sequence led to the amplification of a full coding sequence (Figure [1](#bph13524-fig-0001){ref-type="fig"}A), which was submitted to GenBank under the accession number KP756901.

![(A) Amino acid sequence alignment of *Asu*‐ACR‐16 and human‐α7 nAChR subunits. The signal peptide (bright green box), ACh‐binding loops A--F (pink boxes), cys‐loop (yellow box) and transmembrane regions TM1--TM4 (turquoise boxes) are indicated. The vicinal cysteines (black‐edged box) that characterize an α‐subunit are present in the C‐binding loop. The blue‐edged box between TM2 and TM3 represents the region where PNU120596 acts on α7 nAChRs. Green arrows are residues important for positive allosteric modulation of α7 receptors by ivermectin. Grey (and grey outline) arrows are residues important for permeability of α7 receptors to Ca^2^ ^+^. Black (and black outline) arrows are residues affecting α7 receptor desensitization. Residues in C‐binding loop of α7 nAChRs that bind α‐BTX are highlighted in grey. (B) Distance tree showing relationships of ACR‐16 homologues in parasitic nematode species with AChR subunit sequences from *C.elegans*. A neighbour joining tree was generated with deduced amino acid sequence from AChR subunits representative from the ACR‐16, ACR‐8, UNC‐38, UNC‐29 and DEG‐3 group as defined by Mongan *et al.*, ([1998](#bph13524-bib-0047){ref-type="ref"}). Three letter prefixes in AChR subunit names: *Ace*, *Asu*, *Cel*, *Hco*, *Llo*, *Nam*, *Sra* and *Tca*, refer to *A. ceylanicum*, *A. suum*, *C. elegans*, *H. contortus*, *L. loa*, N. americanus, *S. ratti* and *T. canis* respectively. ACR‐16 orthologues are highlighted in red. Numbers at each branch indicate percentage bootstrap values (\>80%) corresponding to 1000 replicates. The scale bar represents substitutions per site. The *Cel‐lgc*‐30 subunit sequence was used as an outgroup**.**](BPH-173-2463-g001){#bph13524-fig-0001}

When we used the *Asu‐acr‐*16 transcript sequence as a query, a [blast]{.smallcaps}P search resulted in the identification of highly conserved (complete or partial) homologous sequences from other parasitic nematode species belonging to Clade III (*T. canis* and *L. loa*), Clade IV (*S. ratti*) and Clade V (*H. contortus*, *A. ceylanicum* and Necator americanus) (Figure [1](#bph13524-fig-0001){ref-type="fig"}B and Supporting Information [S2](#bph13524-supitem-0001){ref-type="supplementary-material"}). The distance tree presented in Figure [1](#bph13524-fig-0001){ref-type="fig"}B indicates the orthologous relationship of the ACR‐16 sequences from parasitic nematodes with the *Cel*‐ACR‐16 sequence and also shows the orthologous relationship to the other nAChR subunits of C elegans. The predicted complete sequences corresponding to ACR‐16 orthologues in parasitic nematodes from Clade III and V were further analysed in a structural alignment. All amino acid sequences were found to share typical features of nAChR subunits including a predicted signal peptide, four transmembrane domains, a Cys‐loop motif and a cysteine doublet in the potential agonist site defining them as α‐subunits. Of note is that, despite their phylogenetic separation, ACR‐16 sequences from Clade III and Clade V species were found to be highly conserved (i.e. 80% identities between *Asu*‐ACR‐16 and *Hco*‐ACR‐16), suggesting that their pharmacology may also be similar.

Asu‐ACR‐16 sequence suggests pharmacological differences to host mammalian α7 nAChRs {#bph13524-sec-0018}
------------------------------------------------------------------------------------

Alignment of the *Asu*‐ACR‐16 amino acid sequence with that of human‐α7 nAChRs using the Clustal Omega online alignment tool (Sievers *et al.*, [2011](#bph13524-bib-0056){ref-type="ref"}) showed *Asu*‐ACR‐16 and human‐α7 receptors share 44.90% identity in their amino acid sequences. Figure [1](#bph13524-fig-0001){ref-type="fig"}A shows the amino acid sequence alignment of *Asu*‐ACR‐16, which is compared with that of human‐α7 receptors (Raymond *et al.*, [2000](#bph13524-bib-0050){ref-type="ref"}; Touroutine *et al.*, [2005](#bph13524-bib-0059){ref-type="ref"}). *Asu*‐ACR‐16 has the characteristic vicinal cysteine residues (Y‐x‐C‐C) found in the C‐loop of most nAChR α‐subunits; these C‐C residues play an essential role in ACh binding (Kao *et al.*, [1984](#bph13524-bib-0033){ref-type="ref"}). Significantly, the Y‐x‐C‐C residues of the C‐loop of *Asu*‐ACR‐16 (Supporting Information [S2](#bph13524-supitem-0001){ref-type="supplementary-material"}) differ from the C‐loop of the levamisole receptor α‐subunits, *Cel*‐UNC‐38 and *Cel*‐ACR‐13, which have a Y‐x‐x‐C‐C motif (Mongan *et al.*, [1998](#bph13524-bib-0047){ref-type="ref"}); this C‐loop difference encouraged our view that the *Asu*‐ACR‐16 nAChR would differ in its pharmacology from that of the levamisole receptors.

We were further encouraged to investigate the pharmacology of *Asu*‐ACR‐16 because of other significant differences in amino acid residues which are known to affect activation, desensitization and modulation in α7 nAChRs. For example, Figure [1](#bph13524-fig-0001){ref-type="fig"}A shows four amino acids (black and black outline arrows in the TM2 region known as L247, V251, L254 and L255 when mature peptide numbering of α7 subunits is used) that change the desensitization of α7 receptors (Revah *et al.*, [1991](#bph13524-bib-0051){ref-type="ref"}; Bertrand *et al.*, [1992](#bph13524-bib-0008){ref-type="ref"}; Corringer *et al.*, [1999b](#bph13524-bib-0020){ref-type="ref"}). Note that only the first of these (L247) is conserved in *Asu*‐ACR‐16. Consequently, we chose to investigate the rate of desensitization of *Asu*‐ACR‐16. Other amino acid differences between the α7 and the levamisole α‐receptor subunits, which we describe subsequently, suggest that the *Asu*‐ACR‐16 receptor pharmacology will be different.

Ubiquitous tissue and single‐cell expression of ACR‐16 in *Asu* {#bph13524-sec-0019}
---------------------------------------------------------------

We examined the distribution of *Asu*‐ACR‐16 in dissected adult female *Asu* tissues using RT‐PCR. We found reproducible and clear evidence of expression of *Asu*‐ACR‐16 message in strips of intestine (Figure [2](#bph13524-fig-0002){ref-type="fig"}A; g, gut), sections of the reproductive tract (Figure [2](#bph13524-fig-0002){ref-type="fig"}A; o, oviduct, uterus), whole dissected pharynx (Figure [2](#bph13524-fig-0002){ref-type="fig"}A; p), body muscle strips (Figure [2](#bph13524-fig-0002){ref-type="fig"}A; m) and head (Figure [2](#bph13524-fig-0002){ref-type="fig"}A; h) region. We observed similar expression patterns of *Asu*‐ACR‐16 message in the gut, oviduct, whole pharynx, body muscle strip and head from four other adult female *Asu*. The expression of *Asu*‐ACR‐16 in tissues other than nerves and body muscle tissue, like the non‐excitable tissues of the intestine and reproductive tract (uterus), was not anticipated. But it was reproducible and may be part of an ACh‐mediated paracrine system (Proskocil *et al.*, [2004](#bph13524-bib-0049){ref-type="ref"}; Bschleipfer *et al.*, [2007](#bph13524-bib-0015){ref-type="ref"}) rather than part of a neurotransmitter process. The *Asu*‐ACR‐16 ACh receptor may serve multiple roles in reproduction, digestion, etc., as well as neuromuscular transmission in the parasite.

![Localization of *Asu*‐ACR‐16 in different body tissues of the *A.suum* worm using RT‐PCR and single‐cell RT‐PCR (*n* = 5). **(**A) RT‐PCR analysis of *Asu‐acr‐*16 (lanes 2, 4, 6, 8, 10) and *gapdh* control (lanes 3, 5, 8, 9, 11) in gut (g), oviduct (o), pharynx (p), somatic muscle strip (m) and head region (h). The PCR products size for *acr‐*16 and *gapdh* is 468 and 411 bp respectively. (B) Single‐cell RT‐PCR of *Asu*‐ACR‐16 in pharyngeal muscle (2, 4, 6, 8, 10) and in somatic muscle (1., 3., 5., 7., 9.). RT‐PCR of *gapdh* control in pharyngeal muscle (3, 5, 7, 9, 11) and in somatic muscle (2., 4., 6., 8., 10.). 1, FastRuler High Range DNA ladder; ntc1, no‐template controls for *acr‐*16; ntc2, no‐template controls for *gapdh*.](BPH-173-2463-g002){#bph13524-fig-0002}

Single‐cell RT‐PCR was conducted to further investigate the localization of *Asu*‐ACR‐16 in the pharyngeal and somatic muscle cells of *A.suum*. We used intracellular micropipettes to collect cytoplasm from individual somatic and pharyngeal muscle cells for PCR analysis. We recovered *Asu*‐ACR‐16 message from single body muscle cells but not from pharyngeal muscle cells (Figure [2](#bph13524-fig-0002){ref-type="fig"}B). The presence of *Asu*‐ACR‐16 positive bands in the whole pharynx and absence in single‐cell RT‐PCR samples suggests that *Asu*‐ACR‐16 is present in the neurons of the circum‐pharyngeal nerve ring but not present on pharyngeal muscle cells. In contrast to the pharyngeal muscle cells, we observed that *Asu*‐ACR‐16 expression is widespread in somatic muscle as well as other tissues of the *Ascaris* body, implying tissue‐related functions in addition to a neuromuscular function.

ric‐3 is required for functional expression of Asu‐ACR‐16 {#bph13524-sec-0020}
---------------------------------------------------------

After we cloned *Asu*‐ACR‐16, we examined ancillary protein requirements for its expression in *Xenopus* oocytes. Figure [3](#bph13524-fig-0003){ref-type="fig"} shows the effects of co‐injecting the cRNA for the ancillary proteins: *ric‐*3, *unc‐*50 and *unc‐*74 from *A.suum*; *ric‐*3, *unc‐*50 and *unc‐*74 from H. *contortus* ; and *ric‐*3 from X. *laevis.* We measured oocyte responses to 100 μM ACh. Figure [3](#bph13524-fig-0003){ref-type="fig"}A shows representative traces of inward currents induced by the different combinations of ancillary proteins and *Asu‐acr‐*16. Figure [3](#bph13524-fig-0003){ref-type="fig"}B is a bar chart of the mean ± SEM of the 100 μM ACh responses. Oocytes injected with *Asu‐acr‐*16 cRNA alone did not respond to 100 μM ACh (*n* = 21). The largest currents (*I* ~max~ = 290.6 ± 63.7 nA, *n* = 23) were seen in oocytes where just *ric‐*3 from *A.suum* was co‐injected with *Asu‐acr‐*16: these oocytes had larger current responses to 100 μM ACh than oocytes in which all three of the ancillaries (*ric‐*3, *unc‐*50 and *unc‐*74 from either H. *contortus* or *A.suum*) were injected with *Asu‐acr‐*16*.* The currents were also larger than when just Hco *‐ric‐*3 was co‐injected with *Asu‐acr‐*16, suggesting that there is a species‐selective interaction between *Asu*‐ACR‐16 and *Asu*‐RIC‐3*.* Interestingly, Xle *‐ric‐*3 produced mean currents that lay between those produced by *Ascaris and Haemonchus ric‐*3*.* We concluded that the robust expression of *Asu*‐ACR‐16 in Xenopus oocytes requires *ric‐*3, but not *unc‐*50 and *unc‐*74.

![Effects of the ancillary proteins, RIC‐3, UNC‐50 and UNC‐74, from different nematode species, on *Asu*‐ACR‐16 expression. (A) Sample traces represented as inward currents produced in response to 100 μM ACh. (B) Bar chart (mean ± SEM) showing (left to right) current (in nA) generated in response to 100 μM ACh produced. Control (ctrl): *Asu‐acr‐*16 alone (*n* = 21). Black bar: *Asu‐acr‐*16 plus Hco *‐ric‐*3, *unc‐*50 and *unc‐*74 (*n* = 15). Vertical line fill: *Asu‐acr‐*16 plus *Asu ric‐*3, *unc‐*50 and *unc‐*74 (*n* = 15). Horizontal line fill: *Asu‐acr‐*16 plus Hco *‐ric‐*3 (*n* = 17). Checkered fill: *Asu‐acr‐*16 plus Xle *‐ric‐*3 (*n* = 20). No fill: *Asu‐acr‐*16 plus *Asu‐ric‐*3 (*n* = 23). *Asu‐acr‐*16 on its own did not respond to ACh, and the largest current size was obtained when *Asu‐acr‐*16 was co‐injected with *Asu‐ric‐*3. \* *P* \< 0.05; significantly different as indicated; Tukey\'s multiple comparison tests.](BPH-173-2463-g003){#bph13524-fig-0003}

We also varied the amount of cRNA of *Asu‐acr‐*16 (10--25 ng) and cRNA of *Asu‐ric‐*3 (5--15 ng) injected to test the effects on expression. Supporting Information [S3](#bph13524-supitem-0001){ref-type="supplementary-material"}A, B shows representative current traces and bar charts of mean ± SEM of the current responses. The largest response (1062 ± 94.1 nA, *n* = 6) was obtained from oocytes injected with 25 ng *Asu‐acr‐*16 and 5 ng *Asu‐ric‐*3. We observed that the responses were dependent on the amounts of *Asu‐acr‐*16 and *Asc‐ric‐*3 injected and that increased *ric‐*3 did not overcome the effects of reduced *acr‐*16. All subsequent recordings were carried out on oocytes in which 25 ng *Asu‐acr‐*16 was co‐injected with 5 ng *Asu‐ric‐*3.

Asu‐ACR‐16 forms a nicotine‐sensitive but levamisole‐insensitive nAChR {#bph13524-sec-0021}
----------------------------------------------------------------------

Figure [4](#bph13524-fig-0004){ref-type="fig"} shows the rank order potency series for a selection of nine nicotinic agonists and eight cholinergic anthelmintic agonists tested on the expressed *Asu*‐ACR‐16 nAChR. The nicotinic and anthelmintic agonists were tested at 100 μM, except for tribendimidine, which was tested at a concentration of 30 μM due to its limited solubility. Representative traces of inward currents induced by each nicotinic or anthelmintic agonist are shown along with their mean ± SEM normalized values as bar charts. Nicotine, cytisine, 3‐bromocytisine and epibatidine were the most potent (\>80% of the control ACh current), whereas DMPP was least potent (\<20% of the control ACh current). Choline, betaine, lobeline and A844606 were not active on the *Asu*‐ACR‐16 nAChR. With the exception of oxantel, which showed a very weak agonist effect (\<10% of the control ACh current), the *Asu*‐ACR‐16 nAChR was not activated by any of the other anthelmintic drugs tested (morantel, levamisole, methyridine, thenium, bephenium, tribendimidine and pyrantel). The rank order potency series for agonists and anthelmintics on *Asu*‐ACR‐16 when normalized to the internal standard control 100 μM ACh current was as follows: *nicotine* \~ *cytisine* \~ 3*‐bromocytisine* \~ *epibatidine* \> *DMPP* \> *oxantel* \>\> \> *choline* = *betaine* = *lobeline* = *A*844606 = *morantel* = *levamisole* = *methyridine* = *thenium* = *bephenium* = *tribendimidine* = *pyrantel.* Nicotine was among the most potent agonists, while none of the cholinomimetic anthelmintics produced any effect, except for the small effect of oxantel. This agonist potency series shows that this nAChR is distinct from the levamisole receptors of nematodes.

![Effects of nAChR agonists and anthelmintics on *Asu*‐ACR‐16. Sample traces and bar chart (mean ± SEM) showing rank order potency series for nAChR agonists: nicotine (nic), cytisine (cyt), 3‐bromocytisine (3‐bc), epibatidine (epi), DMPP, choline (cho), betaine (bet), lobeline (lobe) and A844606; and cholinergic anthelmintics: oxantel (oxa), morantel (mor), levamisole (lev), methyridine (met), thenium (the), bephenium (beph), tribendimidine (tbd) and pyrantel (pyr); on *Asu*‐ACR‐16. Overall, the rank order potency series for agonists and anthelmintics on *Asu*‐ACR‐16 when normalized to the control 100 μM ACh current was as follows: 100 μM nic (*n* = 21) \~ 100 μM cyt (*n* = 21) \~ 100 μM 3‐bc (*n* = 15) \~ 100 μM epi (*n* = 15) \> 100 μM DMPP (*n* = 21) \> 100 μM oxa (*n* = 36 ) \>\>\> 100 μM cho (*n* = 15) = 100 μM bet (*n* = 15) = 100 μM lobe (*n* = 15) = 100 μM A844606 (*n* = 15) = mor (*n* = 21) = 100 μM lev (*n* = 21) = 100 μM met (*n* = 15) = 100 μM the (*n* = 15) = 100 μM beph (*n* = 15) = 30 μM tbd (*n* = 15) = 100 μM pyr (*n* = 15). \* *P* \< 0.05; significantly different as indicated; Tukey\'s multiple comparison tests.](BPH-173-2463-g004){#bph13524-fig-0004}

Asu‐ACR‐16 desensitization {#bph13524-sec-0022}
--------------------------

Desensitization was a feature of the *Asu*‐ACR‐16 receptor responses and was characterized by the peak and waning current responses observed during maintained (for 10 s) agonist applications. We observed receptor desensitization with all potent agonists. The time constants for desensitization observed with different agonists are shown in Figure [5](#bph13524-fig-0005){ref-type="fig"}: the mean time constants for desensitization rates ranged between 6.2 and 12.6 s, with the time constant for desensitization depending on the agonist and significantly higher for ACh than for epibatidine. However, these time constants were markedly longer than the vertebrate α7 receptor, which has desensitization time constants in the 230--1300 ms range (McCormack *et al.*, [2010](#bph13524-bib-0043){ref-type="ref"}): the slower desensitization rates may be explained in part by the absence of the amino acids: V251, L254 and L255 in *Asu*‐ACR‐16.

![*Asu*‐ACR‐16 desensitization rate constant fit. Bar chart (mean ± SEM) showing *Asu*‐ACR‐16 desensitization in response to ACh, 3‐bromocytisine (3‐bc), cytisine (cyt), nicotine (nic) and epibatidine (epi). The rank order for *Asu*‐ACR‐16 time constants of desensitization was as follows: 100 μM ACh (12.6 ± 2.1 s, *n* = 6) \~ 100 μM 3‐bc (11.2 ± 2.8 s, *n* = 6) \~ 100 μM cyt (7.3 ± 0.7 s, *n* = 6) \~ 100 μM nic (6.6 ± 1.0 s, *n* = 4) \~ 100 μM epi (6.2 ± 0.8 s, *n* = 6). *Insert*: Sample trace with red line signifying desensitization fit. \* *P* \< 0.05; significantly different as indicated; Tukey\'s multiple comparison tests.](BPH-173-2463-g005){#bph13524-fig-0005}

Nicotine as a potent agonist {#bph13524-sec-0023}
----------------------------

Figure [6](#bph13524-fig-0006){ref-type="fig"} shows representative recordings and concentration--response relationships of inward currents induced by the application of different concentrations of ACh (Figure [6](#bph13524-fig-0006){ref-type="fig"}A), top trace, and nicotine (Figure [6](#bph13524-fig-0006){ref-type="fig"}A), lower trace. The first application of an agonist for each new recording was always 100 μM ACh, which was used as the internal standard for normalization. The EC~50~ for nicotine (4.5 ± 0.2 μM, *n* = 6) was statistically significantly smaller than that for ACh (EC~50~ of 5.9 ± 0.1 μM, *n* = 6), which, on this basis, nicotine is more potent than ACh. Interestingly, there was no significant difference between the maximum response for nicotine (*I* ~max~ of 82.5 ± 3.4%, *n* = 6) and that for ACh (*I* ~max~ of 82.7 ± 2.4%, *n* = 6). There was also no significant difference between the Hill slopes, *n* ~*H*~, for both nicotine and ACh. However, both the nicotine and ACh concentration--response curves were very steep, with Hill slopes, *N* ~*H*~, of 3.4 ± 0.2, *n* = 6, for nicotine and 3.9 ± 0.3, *n* = 6, for ACh, showing strong cooperativity consistent with homomeric receptors containing multiple ligand binding sites.

![Nicotine (nic) and ACh concentration--response relationships for *Asu*‐ACR‐16 in the absence of antagonists. (A) Sample traces for ACh (top trace) and nicotine (lower trace) dose--response relationships for *Asu*‐ACR‐16. (B) ACh and nic dose--response curves for *Asu*‐ACR‐16. EC~50~ values (mean ± SEM, μM) were 5.9 ± 0.1 for ACh, Hill slope (*n* ~*H*~) = 3.9 ± 0.3, *n* = 6, and 4.5 ± 0.2 for nic, *n* ~*H*~ = 3.4 ± 0.2, *n* = 6.](BPH-173-2463-g006){#bph13524-fig-0006}

Rank order antagonist potencies: Asu‐ACR‐16 is not sensitive to α‐BTX {#bph13524-sec-0024}
---------------------------------------------------------------------

We tested 10 μM concentrations of eight nAChR antagonists of mammalian or nematode receptors on the expressed *Asu*‐ACR‐16 nAChR. The antagonists were α‐bungarotoxin (α‐BTX), dihydro‐β‐erythroidine (DHβE), d‐tubocurarine (dTC), hexamethonium, mecamylamine, methyllycaconitine (MLA), derquantel, and paraherquamide. The mean % inhibition of the control 100 μM ACh current response was used to determine the rank order potency of the antagonists. α‐BTX, an α7 receptor selective antagonist, had little effect on the *Asu*‐ACR‐16 receptor and was the least potent (inhibition, 5.5 ± 0.8% *n* = 6) antagonist in the rank order series. In this respect, the *Asu*‐ACR‐16 receptor was unlike the mammalian α7 nAChR. Mecamylamine, MLA and dTC were the most potent. The rank order of potency (Figure [7](#bph13524-fig-0007){ref-type="fig"}A) was *mecamylamine* = *MLA* = *dTC* \> *paraherquamide* \~ *derquantel* \~ *hexamethonium* \~ *DHβE* \> *α‐BTX.*

![(A) Effects of selected nAChR antagonists on *Asu*‐ACR‐16‐mediated ACh responses. Bar chart showing effects of selected nAChR antagonists on *Asu*‐ACR‐16. Results were expressed as mean ( ± SEM) % inhibition of currents elicited by 100 μM ACh, *n* = 6, for all antagonists. dTC, mecamylamine (mec) and MLA completely blocked *Asu*‐ACR‐16‐mediated ACh responses, while paraherquamide (para), derquantel (der), hexamethonium (hexa) and DHβE only produced a partial block of *Asu*‐ACR‐16‐mediated ACh responses and α‐BTX produced an almost insignificant block of *Asu*‐ACR‐16‐mediated ACh responses. Rank order potency series for the nAChR antagonists each tested at a concentration of 10 μM was as follows: mecamylamine (*n* = 6) = MLA (*n* = 6) ≈ dTC (*n* = 6) \> paraherquamide (*n* = 6) \~ derquantel (*n* = 6) \~ hexamethonium (hexa) (*n* = 6) \~ DHβE (*n* = 6) \> α‐BTX (*n* = 6). \* *P* \< 0.05; significantly different as indicated; Tukey\'s multiple comparison tests. We used ANOVA and Bartlett\'s test for variance inhomogeneity and found no significant difference and Tukey\'s multiple comparison tests. (B) Dose--response relationships for *Asu*‐ACR‐16 in the presence of antagonists. (B1) Sample traces for ACh concentration--response relationships for *Asu*‐ACR‐16 in the presence of 1 μM derquantel and 1 μM DHβE. (B2) ACh concentration--response plots for *Asu*‐ACR‐16 in the presence of 1 μM derquantel and 1 μM DHβE. Derquantel caused a reduction in the maximum response, but no change in EC~50~, whereas DHβE caused both a reduction in the maximum response and a right shift in the EC~50~.](BPH-173-2463-g007){#bph13524-fig-0007}

Non‐competitive derquantel antagonism and mixed antagonism of DHβE {#bph13524-sec-0025}
------------------------------------------------------------------

We tested the effects of the nAChR antagonists, derquantel and DHβE on ACh (Figure 7B1). The concentration--response plots (Figure 7B2) show that derquantel acts as a non‐competitive antagonist, with 1 μM derquantel producing a statistically significant reduction in the maximum response, but no significant change in the EC~50~. *I* ~max~ and EC~50~ values were respectively 82.7 ± 2.4% and 5.9 ± 0.1 μM, *n* = 6, for ACh and 63.8 ± 2.8% and 6.2 ± 0.5 μM, *n* = 6, for derquantel. DHβE produced mixed competitive and non‐competitive antagonism (Figure 7B2) characterized by a significant right shift in the EC~50~ and a statistically significant reduction of the maximum response. EC~50~ and *I* ~max~ values were respectively 5.9 ± 0.1 μM and 82.7 ± 2.4%, *n* = 6, for ACh and 29.0 ± 1.0 μM and 58.0 ± 3.1%, *n* = 6, for DHβE. These observations suggest that antagonists of this receptor act at more than one site that may include the agonist‐binding site and/or a different allosteric site.

PAMs of human α7 nAChRs inhibit Asu‐ACR‐16 responses {#bph13524-sec-0026}
----------------------------------------------------

Ion channel receptor opening may be increased (agonists) or decreased (competitive antagonists) by drugs binding to the ligand binding site, or the opening can be increased by PAMs or decreased by negative allosteric modulators binding to a site other than the ligand binding site (allosteric sites). Ivermectin and genistein are α7 receptor type 1 PAMs (Sattelle *et al.*, [2009](#bph13524-bib-0053){ref-type="ref"}), which increase the response to a fixed concentration of an agonist by increasing the amplitude of the current response; PNU120596 is an α7 receptor type 2 PAM (Kalappa and Uteshev, [2013](#bph13524-bib-0031){ref-type="ref"}) whose action is characterized by both an increased amplitude of response and the reduction of desensitization of the current response to a fixed concentration of agonist.

We were interested to see if ivermectin, genistein and PNU120596 were PAMs of the *Asu*‐ACR‐16. We tested the effects of ivermectin (10 μM), genistein (3 μM) and PNU120596 (3 μM) separately on responses to 10, 30 and 100 μM ACh (Supporting Information [S4](#bph13524-supitem-0001){ref-type="supplementary-material"}). We did not observe potentiation in any experiment, but we saw modest reductions in the amplitudes of the responses. Figure [8](#bph13524-fig-0008){ref-type="fig"} shows bar charts of the mean ± SEM \[*n* = 6 (ivermectin), *n* = 6 (genistein), *n* = 6 (PNU120596)\] currents of the control and test responses in the presence of the allosteric modulator. Two‐way ANOVA showed that ivermectin, genistein and PNU120596 had a statistically significant inhibitory effect on *Asu*‐ACR‐16 ACh responses. This inhibitory effect of ivermectin, genistein and PNU120596 was opposite to the stimulatory effect on mammalian α7 receptors (Sattelle *et al.*, [2009](#bph13524-bib-0053){ref-type="ref"}).

![Effects of PAMs of human‐α7 on *Asu*‐ACR‐16‐mediated ACh responses. Bar charts showing blocking actions of human‐α7 PAMs; (A) 10 μM ivermectin (*n* = 6), (B) 3 μM genistein (*n* = 6) and (C) 3 μM PNU120596 (*n* = 6), on the responses of *Asu*‐ACR‐16 to ACh. The type 1 PAMs, ivermectin and genistein, as well as the type 2 PAM, PNU120596, caused a reduction in *Asu*‐ACR‐16 responses to 10, 30 and 100 μM ACh, with the reduction being more pronounced at 10 than at 30 or 100 μM ACh.](BPH-173-2463-g008){#bph13524-fig-0008}

Calcium permeability of Asu‐ACR‐16 {#bph13524-sec-0027}
----------------------------------

The calcium permeability of nAChRs varies and relates to the channel pore region formed by the TM2 domain of the subunit (Corringer *et al.*, [1999a](#bph13524-bib-0019){ref-type="ref"}; Tapia *et al.*, [2007](#bph13524-bib-0058){ref-type="ref"}). We tested the calcium permeability of the *Asu*‐ACR‐16 receptor by determining the shift in the reversal potential of the current--voltage (I--V) plot following a change in the concentration of Ca^2^ ^+^ in the extracellular solution (Supporting Information [S5](#bph13524-supitem-0001){ref-type="supplementary-material"}). Increasing the concentration of Ca^2^ ^+^ from 1 to 10 mM produced an inward rectification of the current through the *Asu*‐ACR‐16 receptor and a small positive shift of the I--V plot of 2.4 ± 2.1 mV (*n* = 6). A shift of 2.4 mV indicates relative calcium permeability (*P* ~*Ca*~/*P* ~*Na*~) of 0.4 when calculated from the GHK equation. The α7 receptor is much more permeable to calcium than the *Asu*‐ACR‐16 receptor. The *P* ~*Ca*~/*P* ~*Na*~ reported for α7 nAChRs is 20, calculated from a 29 ± 3 mV shift under similar conditions (Séquéla *et al.*, [1993](#bph13524-bib-0055){ref-type="ref"}), which was significantly (two‐tailed *t*‐test) bigger than the 2.4 mV shift observed for *Asu‐ACR‐*16.

Discussion {#bph13524-sec-0028}
==========

This study reports for the first time the reconstitution in the *Xenopus* oocyte expression system of a fully functional homomeric nAChR, ACR‐16, from a parasitic nematode. This finding is of significant importance in anthelmintic drug discovery in that it provides an efficient platform for screening anthelmintic compounds.

Comparison of pharmacology of Asu‐ACR‐16 with Cel‐ACR‐16 {#bph13524-sec-0029}
--------------------------------------------------------

Previous work on the functional reconstitution in *Xenopus* oocytes and pharmacological characterization of ACR‐16 has focused on the model nematode, C. elegans (Ballivet *et al.*, [1996](#bph13524-bib-0003){ref-type="ref"}). In agreement with Ballivet *et al.* ([1996](#bph13524-bib-0003){ref-type="ref"}), *Asu*‐ACR‐16 was more sensitive to nicotine than ACh, but insensitive to levamisole and pyrantel. However, the Hill slopes for nicotine (*n* ~*H*~ = 3.4 ± 0.2, *n* = 6) and ACh (*n* ~*H*~ = 3.9 ± 0.3, *n* = 6) concentration--response curves for *Asu*‐ACR‐16 were slightly steeper than those reported for *Cel*‐ACR‐16 (*n* ~*H*~ = 2.2 for nicotine and *n* ~*H*~ = 2.1 for ACh). In any case, the Hill slopes for both *Asu*‐ACR‐16 and *Cel*‐ACR‐16 reveal strong cooperativity associated with homomeric receptors. The steeper Hill slopes for *Asu*‐ACR‐16 may account for its higher sensitivity (as shown by EC~50~ values) to nicotine and ACh when compared with those for *Cel*‐ACR‐16 (*Asu*‐ACR‐16\'s EC~50~ values were 4.5 ± 0.2 μM, *n* = 6, for nicotine and 5.9 ± 0.1 μM, *n* = 6, for ACh. On the other hand, for *Cel*‐ACR‐16, EC~50~ values were 12.6 μM for nicotine and 55.4 μM for ACh. Despite the high degree of sequence identity (74.75% identity) between *Asu‐*ACR‐16 and *Cel*‐ACR‐16 (Ce21), there exist significant differences in terms of the antagonist pharmacology of these two receptors. In accordance with Ballivet *et al.* ([1996](#bph13524-bib-0003){ref-type="ref"}), *Asu*‐ACR‐16 was nearly insensitive to α‐BTX, but highly sensitive to dTC. In contrast, *Asu‐*ACR‐16 was highly sensitive to MLA, but moderately sensitive to hexamethonium and DHβE.

Comparison of pharmacology of Asu‐ACR‐16 with α7 nAChRs {#bph13524-sec-0030}
-------------------------------------------------------

Alignment of *Asu*‐ACR‐16 with human α7 nAChRs shows similarities but important differences in amino acid residues, suggesting differences in their pharmacologies. We findsimilarities in agonist sensitivity to ACh, nicotine and epibatidine of *Asu*‐ACR‐16 and α7 receptors (Raymond *et al.*, [2000](#bph13524-bib-0050){ref-type="ref"}; Li *et al.*, [2011](#bph13524-bib-0039){ref-type="ref"}). However, *Asu*‐ACR‐16 was insensitive to the α7‐selective agonist, A844606. *Asu*‐ACR‐16 was highly sensitive to MLA just like α7 (Briggs *et al.*, [1995](#bph13524-bib-0013){ref-type="ref"}), but in contrast to the sensitivity of α7 receptors to α‐BTX (Zhao *et al.*, [2003](#bph13524-bib-0063){ref-type="ref"}), we observed *Asu*‐ACR‐16 to be quite insensitive to α‐BTX. The PAMs of α7 (ivermectin, genistein and PNU120596) were inhibitory on *Asu*‐ACR‐16. Lastly, we found that the relative calcium permeability ratio of *Asu*‐ACR‐16 was about 50× smaller than that of the α7 receptor (Séquéla *et al.*, [1993](#bph13524-bib-0055){ref-type="ref"}). The pharmacology of *Asu*‐ACR‐16 receptors is thus different to that of α7 nAChRs, indicating that the *Asu*‐ACR‐16 receptor has potential as a drug target site.

Comparison of pharmacology of Asu‐ACR‐16 with levamisole receptors {#bph13524-sec-0031}
------------------------------------------------------------------

*Asu*‐ACR‐16 is different from the classical cholinergic levamisole receptor. The levamisole receptor subtypes are composed of different mixtures of heterologous subunits (UNC‐29, UNC‐38, ACR‐8, LEV‐1, ACR‐13 and UNC‐63) (Martin *et al.*, [2012](#bph13524-bib-0042){ref-type="ref"}), whereas *Asu*‐ACR‐16 consists of only one subunit (ACR‐16). Unlike the levamisole receptors, which are sensitive to levamisole but insensitive to nicotine, *Asu*‐ACR‐16 is sensitive to nicotine but insensitive to levamisole. All three ancillary proteins, RIC‐3, UNC‐50 and UNC‐74, are required for robust expression of levamisole‐sensitive receptors (Boulin *et al.*, [2008](#bph13524-bib-0012){ref-type="ref"}), while ACR‐16 requires only RIC‐3 for optimal expression in Xenopus oocytes (Sattelle *et al.*, [2009](#bph13524-bib-0053){ref-type="ref"}; Bennett *et al.*, [2012](#bph13524-bib-0006){ref-type="ref"}).

Another important difference between *Asu*‐ACR‐16 and the levamisole receptor can be seen in their antagonist pharmacologies. The levamisole receptor was only slightly inhibited by the nAChR antagonist, DHβE (Richmond and Jorgensen, [1999](#bph13524-bib-0052){ref-type="ref"}), whereas *Asu*‐ACR‐16 was strongly inhibited by DHβE. MLA and hexamethonium are also less potent on levamisole receptors. Because the pharmacology of ACR‐16 is different from the levamisole receptors, a selective anthelmintic directed at ACR‐16 may have the appropriate properties to bypass resistance.

Differences in α‐BTX potency, allosteric modulation and Ca^2^ ^+^ permeability {#bph13524-sec-0032}
------------------------------------------------------------------------------

Site‐directed mutagenesis of nAChR subunits has been exploited as one of the tools in understanding the pharmacological differences between nAChR types. In a bid to provide reasons for the differences between the pharmacology of α7 receptors and *Asu*‐ACR‐16, we reviewed and compared the amino acids known to affect receptor pharmacology. In α7 for instance, the amino acids critical for α‐BTX binding are ERFYECCKEPYPD in the C‐loop (Balass *et al.*, [1997](#bph13524-bib-0002){ref-type="ref"}). The corresponding residues in *Asu*‐ACR‐16 are E**K**FY**D**CC**P**EPYPD: the RK, ED and KP substitutions may explain why α‐BTX is not as potent as an antagonist of the *Asu*‐ACR‐16 receptor.

There are seven residues in α7 nAChRs important for positive allosteric modulation by ivermectin (Figure [1](#bph13524-fig-0001){ref-type="fig"}A, dark green arrows). Remarkably, none of these amino acids are conserved in *Asu*‐ACR‐16, which may explain why a positive allosteric effect of ivermectin for *Asu*‐ACR‐16 was not detected. Mutations in four of these residues (A225D, Q272, T456Y and C459) caused a significant reduction in the potency of ivermectin as a PAM, while mutations in the other three (S222M, M253L and S276V) caused ivermectin to act as an antagonist (Collins and Millar, [2010](#bph13524-bib-0018){ref-type="ref"}). *Asu‐*ACR‐16 contains the M253L substitution consistent with the observed inhibitory effect of ivermectin. Furthermore, we found that PNU120596 was not an allosteric modulator of *Asu*‐ACR‐16, in contrast to its action at α7 receptors. The amino acid residues between TM2 and TM3 in α7 responsible for PNU120596 positive allosteric modulation (AEIMPATSDS) (Bertrand *et al.*, [2008](#bph13524-bib-0007){ref-type="ref"}) are replaced with **S**EI**S**P**P**TS**EA** in *Asu‐*ACR‐16 (blue‐edged box, Figure [1](#bph13524-fig-0001){ref-type="fig"}A). These differences may account for the lack of positive allosteric modulation by PNU120596 in *Asu‐*ACR‐16. The amino acid differences in allosteric modulatory sites may allow for the design of selective drugs targeted at *Asu*‐ACR‐16.

Three residues, E237, L254 and L255, play key roles in the Ca^2^ ^+^ permeability of α7 nAChRs (grey and grey outline arrows, Figure [1](#bph13524-fig-0001){ref-type="fig"}A). In these receptors, mutations E237A, L254R/T and L255R/T/G cause a reduction in Ca^2^ ^+^ permeability (Bertrand *et al.*, [1993](#bph13524-bib-0009){ref-type="ref"}). When compared with *Asu*‐ACR‐16, only one (E237) of these three residues is conserved. Amino acid differences at one or more positions may account for the reduction in the Ca^2^ ^+^ permeability of the *Asu*‐ACR‐16 compared with the α7 receptor.

Ubiquitous distribution of Asu‐ACR‐16 receptor and its function {#bph13524-sec-0033}
---------------------------------------------------------------

ACR‐16 has been identified as one of the proteins required for the excitatory current at the neuromuscular junction of C. elegans (Richmond and Jorgensen, [1999](#bph13524-bib-0052){ref-type="ref"}; Francis *et al.*, [2005](#bph13524-bib-0024){ref-type="ref"}). In fact, *acr‐*16 null mutants show nearly normal motor behaviour. Severe locomotion deficits were, however, seen with *acr‐*16:*unc‐*63 or *acr‐*16:*unc‐*29 double mutants (Touroutine *et al.*, [2005](#bph13524-bib-0059){ref-type="ref"}; Li *et al.*, [2014](#bph13524-bib-0040){ref-type="ref"}), showing that, in combination with other subunits, its function was essential.

The ubiquitous distribution of the *Asu*‐ACR‐16 message in tissues like the intestine and reproductive tract suggests that this receptor has functions which are not limited to regulation of fast neuromuscular transmission. The presence of *Asu*‐ACR‐16 in non‐excitable tissues suggests that *Asu*‐ACR‐16 also has slower paracrine/autocrine and homeostatic or differentiation functions associated with digestion and reproduction (Kawashima and Fujii, [2008](#bph13524-bib-0035){ref-type="ref"}). A paracrine and endocrine intestinal function for ACh is also supported by the presence of an organized distribution of acetylcholinesterase just beneath and adjacent to the intestinal epithelium (Lee, [1996](#bph13524-bib-0038){ref-type="ref"}). The wide tissue distribution of *Asu*‐ACR‐16 message suggests that a selective agonist may have advantages as an anthelmintic.

Consideration of Asu‐ACR‐16 as a drug target {#bph13524-sec-0034}
--------------------------------------------

Our findings show the *Asu*‐ACR‐16 receptor is pharmacologically different from previously characterized nAChRs and may serve as a potential target for therapeutic drug discovery. Given that *Asu*‐ACR‐16 shares some similarities with the mammalian α7 nAChR in terms of agonist pharmacology, it seems more likely that a drug directed at allosteric modulation sites may be more selective because the actions of α7 PAMs on the *Asu*‐ACR‐16 receptor were clearly different from those observed on the mammalian α7 receptor. This is particularly of interest because in recent years, PAMs have received considerable attention as nAChR‐targeted therapeutic agents (Williams *et al.*, [2011](#bph13524-bib-0061){ref-type="ref"}). The α7 nAChR has been more exploited in this regard because of its implication in cognitive disorders such as Alzheimer\'s disease and schizophrenia, and drugs targeting α7 PAM sites have been suggested to have therapeutic potential for these disorders (Bertrand and Gopalakrishnan, [2007](#bph13524-bib-0010){ref-type="ref"}). Therefore, targeting the corresponding sites in *Asu*‐ACR‐16 may give rise to potential therapeutics which will not affect the mammalian host. It may therefore be possible to identify a suitable novel cholinergic anthelmintic which is 'resistance busting' if it were to activate a vital cholinergic receptor that was composed of different novel nAChR subunits.
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**Figure S1**. Amino acid sequence alignment of *Asu*‐ACR‐16 and *Cel*‐ACR‐16 nAChR subunits. The signal peptide (bright green box), ACh‐binding loops A--F (pink boxes), cys‐loop (yellow box) and transmembrane regions TM1--TM4 (turquoise boxes) are indicated. The vicinal cysteines (black‐edged box) that characterize an α‐subunit are present in the C‐binding loop. The blue‐edged box between TM2 and TM3 represents the region where PNU120596 acts on α7.

**Figure S2**. Alignment of ACR‐16 sequences from *Asu*, *Toxocara canis*, *Loa loa*, *Hco*, *Ancylostoma ceylanicum* and *C.elegans*. Predicted signal peptide sequences are shaded in grey. Amino acids conserved between the different ACR‐16 sequences are highlighted in blue. The Cys‐loop, the four transmembrane regions (TM1--TM4) and the primary agonist‐binding site are noted above the sequence.

**Figure S3**. Effects of varied amounts of *Asu‐acr‐*16 and *Asu‐ric‐*3 on *Asu*‐ACR‐16 expression. (A) Sample traces represented as inward currents produced in response to 100 μM ACh. (B) Bar chart (mean ± SEM) showing current sizes produced by 25 ng *Asu‐acr‐*16 and 5 ng *Asu‐ric‐*3 (1062 ± 94.1, *n* = 6), 10 ng *Asu‐acr‐*16 and 5 ng *Asu‐ric‐*3 (848.8 ± 155.4, *n* = 6), 10 ng *Asu‐acr‐*16 and 10 ng *Asu‐ric‐*3 (727.3 ± 63.1, *n* = 6); 15 ng *Asu‐acr‐*16 and 15 ng *Asu‐ric‐*3 (602.8 ± 106.8, *n* = 6) in response to 100 μM ACh. \* *P* \< 0.05, Tukey\'s multiple comparison tests.

**Figure S4**. Sample traces showing the effects of PAMs of α7; (A) 10 μM ivermectin, (B) 3 μM genistein and (C) 3 μM PNU120596, on *Asu*‐ACR‐16‐mediated ACh responses.

**Figure S5**. Calcium permeability of *Asu*‐ACR‐16 with 30 μM ACh currents: representative I--V plot for oocytes expressing *Asu*‐ACR‐16, showing current change with voltage in 1 mM (black line) and 10 mM (red line) Ca^2+^recording solutions. I--V relationship was plotted using a cubic polynomial equation and interpolated to measure the E~rev~. The mean ± SEM for the positive shift of the I--V plot for six observations was 2.4 ± 2.1 mV, and this corresponded to a relative calcium permeability ratio of 0.4. Insert: magnified view of the I--V fitted line from −10 to 10 mV, showing the E~rev~ in 1 and 10 mM Ca^2+^.
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[^1]: These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al*., [2016](#bph13524-bib-0065){ref-type="ref"}) or the PubChem or Wormbase databases. Entries in the IUPHAR database are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander *et al*., [2015](#bph13524-bib-0064){ref-type="ref"}).
